Author

Zoe Dunn

Observed name: Z. Dunn

Institution: GlaxoSmithKline Research & Development Limited (United Kingdom)

Observed institutions: GlaxoSmithKline (United Kingdom), GlaxoSmithKline Research & Development Limited (United Kingdom)

ORCID: 0009-0003-7064-8953

Observed ORCID: 0009-0003-7064-8953

OpenAlex ID: A5055714307

Evaluation of the predictivity of Acute Oral Toxicity (AOT) structure-activity relationship models

2021 · Kamila Gromek, William Hawkins, et al. · Regulatory Toxicology and Pharmacology · 30

Establishment of a threshold of toxicological concern for pharmaceutical intermediates based on historical repeat-dose data and its application in setting health based exposure limits

2024 · Zoe Dunn, Delorice Murudzwa, et al. · Regulatory Toxicology and Pharmacology · 2

P23-07 Critical aspects for setting health-based exposure limits (HBELs) for TPD-IMiD drugs

2025 · D.S.G. Harte, Z. Dunn, et al. · Toxicology Letters

LP-10 Comparative analysis of occupational exposure limits (OELs) for inhibiting RNA therapeutics

2024 · J. Nunic, L. Wiesner, et al. · Toxicology Letters

P04-04: Toxicological evaluation of 2-(Methylsulfonyl)ethylamine (2-AEMS): genotoxicity, acute and 4-week oral toxicity studies in rats

2023 · K. Blum, Z. Dunn, et al. · Toxicology Letters

Works count: 5

Citation count: 32

H-index: 2

I10-index: 1